tradingkey.logo

Sensus Healthcare Inc

SRTS
查看詳細走勢圖
3.830USD
-0.010-0.26%
收盤 12/19, 16:00美東報價延遲15分鐘
62.97M總市值
虧損本益比TTM

Sensus Healthcare Inc

3.830
-0.010-0.26%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.26%

5天

0.00%

1月

-4.73%

6月

-19.03%

今年開始到現在

-44.65%

1年

-46.06%

查看詳細走勢圖

TradingKey Sensus Healthcare Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Sensus Healthcare Inc當前公司基本面數據相對非常健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名86/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價7.33。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Sensus Healthcare Inc評分

相關信息

行業排名
86 / 208
全市場排名
209 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 3 分析師
買入
評級
7.333
目標均價
+94.52%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Sensus Healthcare Inc亮點

亮點風險
Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
業績增長期
公司處於發展階段,最新年度總收入41.81M美元
估值低估
公司最新PE估值-20.80,處於3年歷史低位
機構減倉
最新機構持股4.72M股,環比減少20.85%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉261.13K股
活躍度增加
近期活躍度增加,過去20天平均換手率-0.03

Sensus Healthcare Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Sensus Healthcare Inc簡介

Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
公司代碼SRTS
公司Sensus Healthcare Inc
CEOSardano (Joseph C)
網址https://sensushealthcare.com/

常見問題

Sensus Healthcare Inc(SRTS)的當前股價是多少?

Sensus Healthcare Inc(SRTS)的當前股價是 3.830。

Sensus Healthcare Inc 的股票代碼是什麼?

Sensus Healthcare Inc的股票代碼是SRTS。

Sensus Healthcare Inc股票的52週最高點是多少?

Sensus Healthcare Inc股票的52週最高點是9.077。

Sensus Healthcare Inc股票的52週最低點是多少?

Sensus Healthcare Inc股票的52週最低點是3.030。

Sensus Healthcare Inc的市值是多少?

Sensus Healthcare Inc的市值是62.97M。

Sensus Healthcare Inc的淨利潤是多少?

Sensus Healthcare Inc的淨利潤為6.65M。

現在Sensus Healthcare Inc(SRTS)的股票是買入、持有還是賣出?

根據分析師評級,Sensus Healthcare Inc(SRTS)的總體評級為買入,目標價格為7.333。

Sensus Healthcare Inc(SRTS)股票的每股收益(EPS TTM)是多少

Sensus Healthcare Inc(SRTS)股票的每股收益(EPS TTM)是-0.184。
KeyAI